- Home
- LPTX vs NB Comparison
LPTX vs NB Comparison
Compare LPTX & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NB
- Stock Information
- Founded
- LPTX 2011
- NB 1987
- Country
- LPTX United States
- NB United States
- Employees
- LPTX N/A
- NB N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NB Metal Mining
- Sector
- LPTX Health Care
- NB Basic Materials
- Exchange
- LPTX Nasdaq
- NB Nasdaq
- Market Cap
- LPTX 119.6M
- NB 116.9M
- IPO Year
- LPTX N/A
- NB N/A
- Fundamental
- Price
- LPTX $0.48
- NB $2.23
- Analyst Decision
- LPTX Buy
- NB Strong Buy
- Analyst Count
- LPTX 3
- NB 2
- Target Price
- LPTX $8.50
- NB $3.63
- AVG Volume (30 Days)
- LPTX 1.5M
- NB 401.5K
- Earning Date
- LPTX 03-17-2025
- NB 03-04-2025
- Dividend Yield
- LPTX N/A
- NB N/A
- EPS Growth
- LPTX N/A
- NB N/A
- EPS
- LPTX N/A
- NB N/A
- Revenue
- LPTX N/A
- NB N/A
- Revenue This Year
- LPTX N/A
- NB N/A
- Revenue Next Year
- LPTX N/A
- NB N/A
- P/E Ratio
- LPTX N/A
- NB N/A
- Revenue Growth
- LPTX N/A
- NB N/A
- 52 Week Low
- LPTX $0.47
- NB $1.27
- 52 Week High
- LPTX $4.79
- NB $4.00
- Technical
- Relative Strength Index (RSI)
- LPTX 19.00
- NB 52.03
- Support Level
- LPTX $0.47
- NB $2.34
- Resistance Level
- LPTX $0.53
- NB $2.55
- Average True Range (ATR)
- LPTX 0.04
- NB 0.29
- MACD
- LPTX 0.07
- NB -0.05
- Stochastic Oscillator
- LPTX 7.42
- NB 18.82
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.